Latest news
FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer - The American Journal of Managed Care® (AJMC®)The American Journal of Managed Care® (AJMC®) · Fri, 07 Aug 2026 16:51:52 GMTReal-world outcomes of first-line pembrolizumab plus chemotherapy in metastatic triple-negative breast cancer with central nervous system metastases: a multicenter cohort from Poland, the Czech Republic and Slovakia | Pieniążek | Reports of Practical Oncol - Via Medica JournalsVia Medica Journals · Mon, 03 Aug 2026 14:02:58 GMTDatroway Wins EU Approval for First-Line Metastatic Triple-Negative Breast Cancer - BioPharm InternationalBioPharm International · Fri, 31 Jul 2026 17:17:31 GMTEuropean Commission Approves First-Line Dato-DXd for Immunotherapy-Ineligible Metastatic TNBC - OncLiveOncLive · Fri, 31 Jul 2026 10:24:43 GMTDatroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy - Business WireBusiness Wire · Fri, 31 Jul 2026 07:00:00 GMTDatroway approved in the EU as only TROP2-directed medicine with overall survival benefit for the 1st-line treatment of patients with metastatic TNBC who are not candidates for immunotherapy - AstraZenecaAstraZeneca · Fri, 31 Jul 2026 02:00:00 GMTFDA Approves Two New Treatments For Metastatic TNBC - Breast Cancer.orgBreast Cancer.org · Wed, 29 Jul 2026 12:32:32 GMT